Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CPT2 | P23786 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27553894 | 1.00 | HMGCR (0.55) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL8095617 | 1.00 | HMGCR (0.55) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL14448847 | 0.79 | HMGCR (0.36) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL16752633 | 0.78 | HMGCR (0.60) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL3188769 | 0.77 | HTT (0.35) | HMGCRCHRM1TBXA2RADRA1ATSHR | |
| SCHEMBL14357445 | 0.77 | FAAH (0.38) | HMGCRCHRM1TBXA2RADRA1ANPSR1 | |
| SCHEMBL27983637 | 0.77 | HMGCR (0.36) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL21272585 | 0.77 | HMGCR (0.46) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL19214603 | 0.77 | PAM (0.39) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 | |
| SCHEMBL11042733 | 0.76 | HMGCR (0.57) | HMGCRCHRM1TBXA2RADRA1ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | H. LUNDBECK A/S (DK) | 2025-12-30 | — | — | US | disclosed |
| EP-4007571-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS FOR USE IN EPILEPSY OR SEIZURES | H LUNDBECK AS (DK) | 2025-06-18 | — | — | EP | disclosed |
| EP-4565228-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| EP-4241843-B1 | ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS | H LUNDBECK AS (DK) | 2025-05-21 | — | — | EP | disclosed |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| WO-2024030960-A2 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | Kojin Therapeutics, Inc. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20240027902-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20040147756-A1 | Optically active fluorine-containing compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1422226-A1 | Optically active fluorine-containing compounds and processes for their production | Tosoh Corporation (JP) | 2004-05-26 | — | — | EP | disclosed |
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-1341745-A1 | RETIFEROL DERIVATIVES AND THEIR USE IN THE TREATMENT OF SKIN DISEASES OR CONDITIONS ASSOCIATED WITH PHOTODAMAGE | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002042247-A1 | RETIFEROL DERIVATIVES AND THEIR USE IN THE TREATMENT OF SKIN DISEASES OR CONDITIONS ASSOCIATED WITH PHOTODAMAGE | F.HOFFMANN-LA ROCHE AG (CH) | 2002-05-30 | — | — | WO | disclosed |
| US-6043385-A | TREATMENT OF PSORIASIS, BASAL CELL CARCINOMAS, DISORDERS OF KERATINIZATION AND KERATOSIS, NEOPLASTIC DISEASES SUCH AS LEUKEMIA, DISORDERS OF THE SEBACEOUS GLANDS SUCH AS ACNE AND SEBORRHOIC DERMATITIS, OSTEOPOROSIS, HYPERPARATHYROIDISM | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | disclosed |
| WO-1999031055-A1 | NOVEL VITAMIN D3 AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-24 | — | — | WO | disclosed |
| CN-1168103-A | Dermatological use of vitamin D derivs. | HOFFMANN LA ROCHE (CH) | 1997-12-17 | — | — | CN | disclosed |
| US-5113477-A | Core, cladding, heat resistance | HITACHI, LTD. (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0226020-A2 | Plastic optical fibers and transparent resin used therefor | HITACHI, LTD. (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | HMGCR 2607/4885CHRM1 666/4885TBXA2R 113/4885 |
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | NR1H2, RFC2, RFC1 | HMGCR 702/4885CHRM1 2316/4885TBXA2R 3142/4885 |
| US-20040147756-A1 | Optically active fluorine-containing compounds and processes for their production | CYP2C19, CYP2F1, CYP2B6 | HMGCR 1014/4885CHRM1 1506/4885TBXA2R 3581/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | HMGCR 2245/4885CHRM1 4732/4885TBXA2R 2444/4885 |
| US-12508239-B2 | Alcohol derivatives as Kv7 potassium channel openers for use in epilepsy or seizures | KCNN3, KCNN1, KCNN2 | HMGCR 3031/4885CHRM1 248/4885TBXA2R 3681/4885 |
| US-12258305-B2 | Alcohol derivatives as Kv7 potassium channel openers | KCNA7, KCNK17, KCNQ1 | HMGCR 3250/4885CHRM1 402/4885TBXA2R 1206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.